Camille Ledford, NP
Adult Health · Hiawassee, GANPI 1235301946
Payments from drug & device makers
Across 125 payments — averaging $18.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$374
- Sanofi-aventis U.S. LLC$246
- Lilly USA, LLC$224
- Otsuka America Pharmaceutical, Inc.$189
- AstraZeneca$164
- Novo Nordisk$150
- plus $1K from 23 others
What the payments were for
- Food & beverage$2,356100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 18 | $374 |
| Sanofi-aventis U.S. LLC | 12 | $246 |
| Lilly USA, LLC | 14 | $224 |
| Otsuka America Pharmaceutical, Inc. | 10 | $189 |
| AstraZeneca | 8 | $164 |
| Novo Nordisk | 9 | $150 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $137 |
| GSK | 6 | $117 |
| Amgen(2 entities) | 6 | $101 |
| Lundbeck LLC | 5 | $92 |
| Mylan Specialty L.p. | 3 | $73 |
| Exact Sciences | 3 | $58 |
| Pfizer | 3 | $48 |
| Amarin Pharma, Inc. | 2 | $44 |
| Axsome Therapeutics, Inc. | 2 | $34 |
| Boehringer Ingelheim | 2 | $32 |
| Esperion Therapeutics, Inc. | 2 | $32 |
| Johnson & Johnson | 2 | $30 |
| Biohaven Pharmaceuticals, Inc. | 2 | $27 |
| Antares Pharma, Inc. | 1 | $27 |
| Abbott | 1 | $24 |
| Idorsia Pharmaceuticals US Inc | 1 | $23 |
| Genentech USA, Inc. | 1 | $19 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $19 |
| Teva Pharmaceuticals USA, Inc. | 1 | $15 |
| Paratek Pharmaceuticals, Inc. | 1 | $15 |
| Bausch Health US, LLC | 1 | $15 |
| Shield Therapeutics Inc | 1 | $14 |
| Eisai Inc. | 1 | $13 |
How this compares
$2,356 in reported general payments places this provider in the 75th percentile of 577 adult health providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 98 | $137,247 |
| EliquisApixaban | 117 | $91,899 |
| FarxigaDapagliflozin Propanediol | 72 | $61,284 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 58 | $59,440 |
| LinzessLinaclotide | 71 | $50,613 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 31 | $35,294 |
| ProliaDenosumab | 20 | $35,064 |
| MyrbetriqMirabegron | 59 | $32,366 |
| MounjaroTirzepatide | 27 | $28,498 |
| JardianceEmpagliflozin | 29 | $26,255 |
| JanuviaSitagliptin Phosphate | 22 | $23,929 |
| XareltoRivaroxaban | 24 | $23,229 |
| RybelsusSemaglutide | 16 | $17,330 |
| Breo ElliptaFluticasone/Vilanterol | 17 | $10,174 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 18 | $9,090 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $150 | $154,577114 claims |
| PfizerEliquis | $48 | $91,899117 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta | $117 | $78,70593 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $164 | $69,36785 claims |
| AbbVieLinzess, Synthroid | $374 | $54,295130 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $246 | $35,29431 claims |
| AmgenProlia | $101 | $35,06420 claims |
| Lilly USA, LLCMounjaro | $224 | $28,49827 claims |
| Boehringer IngelheimJardiance | $32 | $26,25529 claims |
| Johnson & JohnsonXarelto | $30 | $23,22924 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $137 | $5,51611 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 577 adult health providers in Georgia.
Other adult health in Hiawassee
- Patricia KeeganAtlanta$224K
- Diane WirthAtlanta$132K
- Barbara WeberAtlanta$74K
- Terry HackworthAtlanta$49K
- Jenny DicksonCumming$39K
- Rachel NejemLawrenceville$31K
- Melissa BaughcumAthens$23K
- Kristine AdamsMarietta$21K
- Jenina LagascaAtlanta$17K
- Jennifer SheldonMacon$17K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.